Published May 22, 2024 | Version v1
Journal Open

Medical innovations against infectious diseases: strategies and preventive measures, diagnosis and treatment

Authors/Creators

  • 1. Tyumen state medical university Odesskaya, 54, 625023 russia, tyumen
  • 2. Federal State Budgetary Educational Institution of Higher Education «Ingush State University (IngSU)" Medical Faculty 386001, Magas, ZIAZIKOVA. str. 7
  • 3. Saratov State Medical University named after V.I. Razumovsky Street Bolshaya Kazachia 112, 410012, Russia
  • 4. Kursk State Medical University Street Karl Marx 3 | 305004 | Russia
  • 5. First Pavlov State Medical University of St. Petersburg. L'va Tolstogo str. 6-8, Saint Petersburg, 197022, Russia
  • 6. Federal State Budgetary Educational Institution of Higher Education "National Research Ogarev Mordovia State University" 430005, 68 Bolshevistskaya Str., Saransk 430005, Republic of Mordovia, Russia
  • 7. Federal State Budgetary Educational Institution of Higher Education "Astrakhan State Medical University" Medical Faculty 414000, Astrakhan, Bakinskaya str. 121.

Description

Abstract: The article presents an overview of modern medical innovations aimed at combating infectious diseases, which remain one of the main challenges for public health worldwide. The paper examines and analyzes in detail the key strategies of prevention, diagnosis and treatment based on advanced scientific and technological achievements. Special attention is paid to the development and application of vaccines, including innovative approaches to their creation, such as RNA vaccines and vector vaccines, as well as strategies to strengthen the immune system through the development of adjuvants and new delivery methods. To that aim, an extensive review of modern scientific articles, reviews, books and other publications related to medical innovations in the field of combating infectious diseases was carried out. The latest diagnostic methods are being investigated, including the use of molecular technologies, biosensors and artificial intelligence for more accurate and rapid detection of infections. In conclusion, the importance of a continuous innovative approach in combating the growing challenges of infectious diseases on a global scale and the need for global cooperation to effectively overcome these problems is emphasized.

Files

2 Medical innovations against infectious.pdf

Files (253.2 kB)

Name Size Download all
md5:46c3c4767212937c1371369dacf7f980
253.2 kB Preview Download

Additional details

References

  • 1. Stearns SC. Evolutionary medicine: Its scope, interest and potential. Proc R Soc B (2012) 279:4305–21.
  • 2. Grunspan DZ, Moeller KT, Nesse RM, Brownell SE. The state of evolutionary medicine in undergraduate education. Evol Med Public Heal (2019) 2019:82–92.
  • Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, et al. Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer (2017) 17:605–19.
  • 4. Kennedy DA, Read AF. Monitor for COVID-19 vaccine resistance evolution during clinical trials. PloS Biol (2020) 18:1–5.
  • 5. Stenvinkel P, Painer J, Johnson RJ, Natterson-Horowitz B. Biomimetics – nature's roadmap to insights and solutions for burden of lifestyle diseases. J Intern Med (2020) 287:238–51. doi: 10.1111/joim.12982
  • 6. Natterson-Horowitz B, Desmarchelier M, Winkler AS, Carabin H. Beyond zoonoses in one health: Non-communicable diseases across the animal kingdom. Front Public Heal (2022) 9:807186.
  • 7. Pesavento PA, Agnew D, Keel MK, Woolard KD. Cancer in wildlife: Patterns of emergence. Nat Rev Cancer (2018) 18:646–61.
  • Gluckman PD, Low FM, Hanson MA. Anthropocene-related disease the inevitable outcome of progressive niche modification. Evol Med Public Heal (2020) 2020:304–10.
  • 9. Vincze O, Colchero F, Lemaître JF, Conde DA, Pavard S, Bieuville M, et al. Cancer risk across mammals. Nature (2022) 601:263–7.
  • 10. Naffar-Abu Amara S, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, et al. Transient commensal clonal interactions can drive tumor metastasis. Nat Commun (2020) 11:5799
  • 11. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature (2021) 591:639–44.
  • 12. Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol (2020) 17:675–86.
  • 13. Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist (2019) 2(2):141–60.
  • 14. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet (2022) 399:P629–665.
  • 15. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med (2017) 5:291–360
  • Hanretty AM, Gallagher JC. Shortened courses of antibiotics for bacterial infections: A systematic review of randomized controlled trials. Pharmacotherapy (2018) 38:674–87.
  • Hansen E, Read AF. Cancer therapy: Attempt cure or manage drug resistance? Evol Appl (2020) 13:1660–72
  • Graf FE, Palm M, Warringer J, Farewell A. Inhibiting conjugation as a tool in the fight against antibiotic resistance. Drug Dev Res (2019) 80:19–23.
  • 19. Morley VJ, Kinnear CL, Sim DG, Olson SN, Jackson LM, Hansen E, et al. An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen. Elife (2020) 9:1–17.
  • Hansen E, Karslake J, Woods RJ, Read AF, Wood KB. Antibiotics can be used to contain drug-resistant bacteria by maintaining sufficiently large sensitive populations. PloS Biol (2020) 18:1–20.
  • 21. Torres-Barceló C, Turner PE, Buckling A. Mitigation of evolved bacterial resistance to phage therapy. Curr Opin Virol (2022) 53:101201.
  • 22. Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: A renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe (2019) 25:219–32.
  • 23. Kunttu HMT, Runtuvuori-Salmela A, Sundell K, Wiklund T, Middelboe M, Landor L, et al. Bacteriophage resistance affects Flavobacterium columnare virulence partly via mutations in genes related to gliding motility and the type IX secretion system. Appl Environ Microbiol (2021) 87:e00812–21.
  • 24. Burmeister AR, Fortier A, Roush C, Lessing AJ, Bender RG, Barahman R, et al. Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance. Proc Natl Acad Sci USA (2020) 117:11207–16.